Association between topical β-blocker use and asthma attacks in glaucoma patients with asthma: a cohort study using a claims database
Association between topical β-blocker use and asthma attacks in glaucoma patients with asthma: a cohort study using a claims database
复制标题
患有哮喘的青光眼患者局部使用β受体阻滞剂与哮喘发作之间的关联：使用索赔数据库的队列研究
DOI：
10.1007/s00417-021-05357-z
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Kawakami K
中科院分区：
文献类型：
--
作者：
Kido A;Miyake M;Akagi T;Ikeda HO;Kameda T;Suda K;Hasegawa T;Hiragi S;Yoshida S;Tsujikawa A;Tamura H;Kawakami K
PurposeTo调查使用局部β-受体阻滞剂和随后的哮喘发作青光眼患者asthma.MethodsThis是一个回顾性纵向队列研究使用行政索赔数据库之间的关联。在JMDC Inc.更新和管理的健康保险索赔数据库中登记的所有20岁或以上患者。（日本东京）。在2011年至2017年期间确定了新处方的青光眼治疗滴眼液的患者。根据处方滴眼液中是否含有β受体阻滞剂，将青光眼患者分为两组：β受体阻滞剂使用者和非β受体阻滞剂使用者。我们调查了既往接受过哮喘治疗的患者的哮喘发作发生率是否在两组之间存在差异。ResultsWe将17，666例患者分为β受体阻滞剂使用组和12，609例非β受体阻滞剂使用组。β受体阻滞剂组580例（3.28%）和非β受体阻滞剂组847例（6.72%）患者在开抗青光眼滴眼液前接受哮喘治疗（P< 0.001）。此外，β受体阻滞剂使用者组94例（0.53%）和非β受体阻滞剂使用者组278例（2.20%）正在接受哮喘治疗（P< 0.001）。哮喘发作的校正危险比为0.73（95%可信区间，0.46- 1.16，P = 0.18），有哮喘治疗史者为1.22（95%可信区间，0.56- 2.70，P = 0.62），与非β-受体阻滞剂使用者组相比。ConclusionOur结果阐明了几例哮喘患者接受局部β-受体阻滞剂治疗青光眼。然而，哮喘发作可能并不明显归因于局部β受体阻滞剂，即使是在目前接受哮喘治疗的青光眼患者中。如果获得充分的知情同意，在没有其他治疗选择的情况下，哮喘患者局部使用β受体阻滞剂可能是一种治疗选择。需要进一步的研究来得出关于这个临床问题的确切结论。
PurposeTo investigate the association between the use of topical β-blockers and subsequent asthma attacks in glaucoma patients with asthma.MethodsThis was a retrospective longitudinal cohort study using an administrative claims database. All patients aged 20 years or older who were registered in the health insurance claims database updated and managed by JMDC Inc. (Tokyo, Japan). Patients who were newly prescribed eye drops for glaucoma treatment were identified between 2011 and 2017. The patients with glaucoma were divided into two groups: β-blocker users and non-β-blocker users, based on the presence of a β-blocker in the prescribed eye drops. We investigated whether the incidence of asthma attacks in patients with previously treated asthma differed between the two groups.ResultsWe categorized 17,666 patients in the β-blocker-user group and 12,609 patients in the non-β-blocker-user group. A total of 580 patients in the β-blocker group (3.28%) and 847 in the non-β-blocker group (6.72%) underwent asthma treatment before the prescription of anti-glaucoma eye drops (P< 0.001). Furthermore, 94 patients in the β-blocker-user group (0.53%) and 278 in the non-β-blocker user group (2.20%) were undergoing current treatment for asthma (P< 0.001). The adjusted hazard ratios of asthma attacks were 0.73 (95% confidence interval, 0.46–1.16,P= 0.18) in patients with a history of asthma treatment and 1.22 (95% confidence interval, 0.56–2.70,P= 0.62) in patients with current asthma treatment, compared to the non-β-blocker-user group.ConclusionOur results clarified that several patients with asthma were prescribed topical β-blockers for glaucoma treatment. However, asthma attacks may not be significantly attributed to topical β-blockers, even in glaucoma patients under current asthma treatment. The administration of topical β-blockers to asthma patients could be a treatment option in the absence of other treatment options, if adequate informed consent is obtained. Further studies are needed to draw a firm conclusion on this clinical question.
登录
查看更多内容
影响因子：
3.4
作者：
Morales, Daniel R.;Dreischulte, Tobias;Guthrie, Bruce
通讯作者：
Guthrie, Bruce
铍接触与肺癌的发生：对巢式病例对照研究结果的重新检验
影响因子：
3.2
作者：
Judith A. Ricci;Elsbeth Chee;A. Lorandeau;Jan Berger;Michael T. Halpern;R. Dirani;J. Schmier;Theodore Darkow;Pamela J. Kadlubek;Hemal Shah;Amy L. Phillips;JenQ P. Marton;Bert Stover;Thomas M. Wickizer;Fred Zimmerman;;Kehoe;Gary M. Franklin;Philip Harber;Lori Crawford;Amarpreet Cheema;Levanto Schacter;Patricia W. Stone;Yunling Du;D. Margison;Douglas J. French;M. Kivimäki;T. Heponiemi;Marko;Elovainio;M. Virtanen;J. Pentti;A. Linna;J. Vahtera;Lora E. Fleming;W. LeBlanc;A. Caban
通讯作者：
A. Caban
影响因子：
13.7
作者：
Tham, Yih-Chung;Li, Xiang;Cheng, Ching-Yu
通讯作者：
Cheng, Ching-Yu
卡替洛尔和噻吗洛尔治疗高眼压症的双盲比较。
DOI：
--
发表时间：
1988
期刊：
American journal of ophthalmology-glaucoma
影响因子：
--
作者：
B. Scoville;Brigitte Mueller;B. G. White;G. Krieglstein
通讯作者：
G. Krieglstein
影响因子：
4.1
作者：
Hashimoto, Yohei;Michihata, Nobuaki;Aihara, Makoto
通讯作者：
Aihara, Makoto